Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai-400085, India.
Homi Bhabha National Institute, Anushaktinagar, Mumbai-400094, India.
Bioconjug Chem. 2021 Mar 17;32(3):430-447. doi: 10.1021/acs.bioconjchem.1c00010. Epub 2021 Feb 25.
Ga-PET has emerged as an important diagnostic tool for precise detection and monitoring of oncological situations. Availability, cost, and radiosynthesis procedure are determining steps for success of a radioisotope/radiopharmaceutical in nuclear medicine. Availability of Ga from a Ge/Ga generator containing a long-lived parent radioisotope (Ge: = 271 days) and an inexpensive, simplified production of Ga-radiopharmaceuticals through kit methodology has allowed smooth accommodation of Ga-PET in clinics. The uncomplicated formulation of Ga-radiopharmaceuticals from a lyophilized, cold kit is an impending breakthrough in clinical PET. The huge success of Ga in neuroendocrine tumor and prostate cancer imaging along with the regulatory approval of respective cold kits has opened a pathway for development of kits for other evolving radiotracers. There is a definite scope for increased participation of commercial manufacturers and distributors of cold kits to spread the potential of Ga worldwide across all the geographical locations and satellite centers.
镓 - PET 已成为精确检测和监测肿瘤情况的重要诊断工具。放射性同位素/放射性药物在核医学中的成功取决于可用性、成本和放射合成程序。含有长寿命母放射性同位素（锗： = 271 天）的锗/镓发生器提供镓的可用性，以及通过试剂盒方法进行廉价、简化的镓放射性药物生产，使得镓 - PET 能够顺利地在临床中应用。从冻干、冷藏试剂盒中简单地配制镓放射性药物是临床 PET 的一个重大突破。镓在神经内分泌肿瘤和前列腺癌成像方面的巨大成功，以及相应的冷藏试剂盒的监管批准，为开发其他放射性示踪剂的试剂盒开辟了道路。商业制造商和冷藏试剂盒经销商的参与度肯定会增加，以将镓的潜力在全球范围内传播到所有地理位置和卫星中心。
